Evogene Ltd
EVGN1.190USD
+0.030+2.59%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
7.94MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Evogene Ltd Unternehmen
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Unternehmensinformationen
BörsenkürzelEVGN
Name des UnternehmensEvogene Ltd
IPO-datumJun 11, 2007
CEODr. Arnon Heyman
Anzahl der mitarbeiter117
WertpapierartOrdinary Share
GeschäftsjahresendeJun 11
Addresse13 Gad Feinstein Street
StadtREHOVOT
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl7638517
Telefon97289311900
Websitehttps://evogene.com/
BörsenkürzelEVGN
IPO-datumJun 11, 2007
CEODr. Arnon Heyman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Leon Yehuda Recanati
Mr. Leon Yehuda Recanati
Independent Director
Independent Director
83.89K
--
Dr. Arnon Heyman
Dr. Arnon Heyman
Chief Executive Officer of Canonic Limited
Chief Executive Officer of Canonic Limited
--
--
Mr. Ofer Haviv
Mr. Ofer Haviv
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Adrian Percy
Dr. Adrian Percy
Independent Director
Independent Director
--
--
Ms. Sarit Firon
Ms. Sarit Firon
Independent Director
Independent Director
--
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Independent Director
Independent Director
--
--
Kenny Green
Kenny Green
Investor Relations
Investor Relations
--
--
Ms. Dorit Kreiner
Ms. Dorit Kreiner
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Dan Michael Falk
Mr. Dan Michael Falk
Independent Director
Independent Director
--
--
Dr. Brian Ember
Dr. Brian Ember
Chief Executive Officer of AgPlenus Limited
Chief Executive Officer of AgPlenus Limited
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Leon Yehuda Recanati
Mr. Leon Yehuda Recanati
Independent Director
Independent Director
83.89K
--
Dr. Arnon Heyman
Dr. Arnon Heyman
Chief Executive Officer of Canonic Limited
Chief Executive Officer of Canonic Limited
--
--
Mr. Ofer Haviv
Mr. Ofer Haviv
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Dr. Adrian Percy
Dr. Adrian Percy
Independent Director
Independent Director
--
--
Ms. Sarit Firon
Ms. Sarit Firon
Independent Director
Independent Director
--
--
Dr. Oded Shoseyov, Ph.D.
Dr. Oded Shoseyov, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2024
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Other
4.00M
47.00%
United States
3.92M
46.00%
Israel
595.77K
7.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
3.63%
Recanati (Leon Yehuda)
0.96%
Jane Street Capital, L.L.C.
0.39%
UBS Financial Services, Inc.
0.22%
Morgan Stanley & Co. LLC
0.17%
Other
94.64%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
3.63%
Recanati (Leon Yehuda)
0.96%
Jane Street Capital, L.L.C.
0.39%
UBS Financial Services, Inc.
0.22%
Morgan Stanley & Co. LLC
0.17%
Other
94.64%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
3.78%
Individual Investor
0.96%
Research Firm
0.71%
Investment Advisor
0.34%
Venture Capital
0.12%
Investment Advisor/Hedge Fund
0.05%
Other
94.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
53
519.37K
5.96%
-412.34K
2025Q1
55
520.29K
6.01%
-409.22K
2024Q4
56
495.82K
9.24%
-272.31K
2024Q3
56
646.41K
12.68%
+45.84K
2024Q2
57
498.30K
80.86%
-140.56K
2024Q1
62
510.64K
10.05%
-122.17K
2023Q4
69
544.86K
11.19%
-474.65K
2023Q3
76
590.60K
14.30%
-53.35K
2023Q2
75
185.66K
4.46%
-461.57K
2023Q1
80
194.62K
4.68%
-499.69K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
316.02K
3.63%
+17.74K
+5.95%
Mar 31, 2025
Recanati (Leon Yehuda)
83.89K
0.96%
--
--
Mar 17, 2025
Jane Street Capital, L.L.C.
33.73K
0.39%
+12.39K
+58.03%
Mar 31, 2025
UBS Financial Services, Inc.
18.75K
0.22%
-3.27K
-14.84%
Mar 31, 2025
Morgan Stanley & Co. LLC
14.56K
0.17%
--
--
Mar 31, 2025
Two Sigma Investments, LP
13.56K
0.16%
+2.40K
+21.53%
Mar 31, 2025
BNP Paribas Securities Corp. North America
12.82K
0.15%
--
--
Mar 31, 2025
XTX Markets LLC
10.18K
0.12%
+10.18K
--
Mar 31, 2025
P&S Vermögensberatungs AG Performance & Sicherheit
10.00K
0.11%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
4.20K
0.05%
--
--
May 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 03, 2022
Merger
10<1
Aug 03, 2022
Merger
10<1
Aug 03, 2022
Merger
10<1
Datum
Art
Verhältnis
Aug 03, 2022
Merger
10<1
Aug 03, 2022
Merger
10<1
Aug 03, 2022
Merger
10<1
